Wayne has been consistent in saying that the company will be reimbursed $25,000 USD for each DurAVR used in trials and that there will be 900-1100 patients enrolled in the pivotal trial.
There's probably a good chance that there will be a ViV trial run concurrently, although whether it will happen in the US or not if it does take place is unknown. I'd guess 50-100 patients for the ViV trial but that's pure speculation on my part.
Ann: Capital Raise, page-90
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.15 |
Change
0.350(2.97%) |
Mkt cap ! $256.8M | |||
| Open | High | Low | Value | Volume |
| $11.80 | $12.15 | $11.21 | $376.0K | 32.22K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 139 | $12.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.15 | 830 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |